|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MAGEB2 |
Gene summary for MAGEB2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MAGEB2 | Gene ID | 4113 |
| Gene name | MAGE family member B2 | |
| Gene Alias | CT3.2 | |
| Cytomap | Xp21.2 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | O15479 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4113 | MAGEB2 | ATC09 | Human | Thyroid | ATC | 4.53e-18 | 6.41e-01 | 0.2871 |
| 4113 | MAGEB2 | ATC13 | Human | Thyroid | ATC | 5.71e-10 | 2.15e-01 | 0.34 |
| 4113 | MAGEB2 | ATC1 | Human | Thyroid | ATC | 1.41e-18 | 7.30e-01 | 0.2878 |
| 4113 | MAGEB2 | ATC5 | Human | Thyroid | ATC | 2.12e-13 | 2.39e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MAGEB2 | SNV | Missense_Mutation | rs758812052 | c.394N>A | p.Val132Ile | p.V132I | O15479 | protein_coding | tolerated(1) | benign(0.003) | TCGA-BH-A0B5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
| MAGEB2 | SNV | Missense_Mutation | novel | c.32N>T | p.Ala11Val | p.A11V | O15479 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MAGEB2 | SNV | Missense_Mutation | rs746022879 | c.8G>A | p.Arg3His | p.R3H | O15479 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-EK-A2IP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| MAGEB2 | SNV | Missense_Mutation | novel | c.862N>T | p.Val288Phe | p.V288F | O15479 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-VS-A8QA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| MAGEB2 | SNV | Missense_Mutation | rs368561784 | c.322G>A | p.Glu108Lys | p.E108K | O15479 | protein_coding | tolerated(0.46) | benign(0) | TCGA-VS-A8QM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| MAGEB2 | SNV | Missense_Mutation | novel | c.64A>G | p.Thr22Ala | p.T22A | O15479 | protein_coding | tolerated(0.25) | benign(0.214) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MAGEB2 | SNV | Missense_Mutation | novel | c.751N>A | p.Asp251Asn | p.D251N | O15479 | protein_coding | deleterious(0.01) | possibly_damaging(0.85) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MAGEB2 | SNV | Missense_Mutation | rs758812052 | c.394N>A | p.Val132Ile | p.V132I | O15479 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AA-A02H-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| MAGEB2 | SNV | Missense_Mutation | c.494G>C | p.Gly165Ala | p.G165A | O15479 | protein_coding | tolerated(0.07) | probably_damaging(0.951) | TCGA-AY-A54L-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| MAGEB2 | SNV | Missense_Mutation | c.68N>T | p.Arg23Leu | p.R23L | O15479 | protein_coding | deleterious(0.03) | benign(0.055) | TCGA-DM-A0XF-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | mayo | CR |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |